Gilead Sciences (GILD) : Comerica Bank reduced its stake in Gilead Sciences by 11.12% during the most recent quarter end. The investment management company now holds a total of 469,213 shares of Gilead Sciences which is valued at $37,377,508 after selling 58,680 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.Gilead Sciences makes up approximately 0.32% of Comerica Bank’s portfolio.
Other Hedge Funds, Including , Tredje Ap-fonden reduced its stake in GILD by selling 21,070 shares or 8.95% in the most recent quarter. The Hedge Fund company now holds 214,242 shares of GILD which is valued at $17,066,518. Gilead Sciences makes up approx 0.71% of Tredje Ap-fonden’s portfolio.Endurance Wealth Management reduced its stake in GILD by selling 650 shares or 1.65% in the most recent quarter. The Hedge Fund company now holds 38,739 shares of GILD which is valued at $3,115,003. Gilead Sciences makes up approx 0.56% of Endurance Wealth Management’s portfolio.Sequoia Financial Advisors boosted its stake in GILD in the latest quarter, The investment management firm added 3,996 additional shares and now holds a total of 43,898 shares of Gilead Sciences which is valued at $3,488,574. Gilead Sciences makes up approx 0.95% of Sequoia Financial Advisors’s portfolio.North Point Portfolio Managers Corpoh reduced its stake in GILD by selling 4,657 shares or 2.14% in the most recent quarter. The Hedge Fund company now holds 213,425 shares of GILD which is valued at $17,456,031. Gilead Sciences makes up approx 3.33% of North Point Portfolio Managers Corpoh’s portfolio.
Gilead Sciences opened for trading at $81.46 and hit $81.64 on the upside on Tuesday, eventually ending the session at $81.47, with a gain of 0.68% or 0.55 points. The heightened volatility saw the trading volume jump to 82,79,418 shares. Company has a market cap of $107,513 M.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.